Mikhail Eydelman Sells 5,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) SVP Mikhail Eydelman sold 5,000 shares of the stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $91.49, for a total transaction of $457,450.00. Following the sale, the senior vice president now owns 28,697 shares of the company’s stock, valued at approximately $2,625,488.53. This represents a 14.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Mikhail Eydelman also recently made the following trade(s):

• On Monday, October 7th, Mikhail Eydelman sold 5,000 shares of Vaxcyte stock. The shares were sold at an average price of $109.27, for a total value of $546,350.00.

Vaxcyte Stock Performance

Shares of Vaxcyte stock traded down $1.25 during trading on Monday, hitting $92.06. The company’s stock had a trading volume of 563,237 shares, compared to its average volume of 905,610. Vaxcyte, Inc. has a 52 week low of $53.83 and a 52 week high of $121.06. The company has a market capitalization of $11.47 billion, a PE ratio of -20.01 and a beta of 0.94. The company has a fifty day simple moving average of $103.45 and a two-hundred day simple moving average of $91.10.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter in the previous year, the firm posted ($0.91) earnings per share. As a group, analysts predict that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Needham & Company LLC reiterated a “buy” rating and issued a $140.00 price objective on shares of Vaxcyte in a research report on Wednesday, November 6th. Mizuho lifted their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a report on Tuesday, September 10th. Bank of America upped their price objective on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. BTIG Research raised their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Finally, Jefferies Financial Group boosted their price target on shares of Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $147.50.

Institutional Trading of Vaxcyte

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC boosted its holdings in Vaxcyte by 23.1% in the third quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company’s stock worth $1,247,954,000 after acquiring an additional 2,052,989 shares in the last quarter. RA Capital Management L.P. raised its position in shares of Vaxcyte by 5.9% in the 3rd quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company’s stock worth $992,914,000 after purchasing an additional 485,436 shares during the last quarter. State Street Corp boosted its stake in Vaxcyte by 1.1% in the 3rd quarter. State Street Corp now owns 3,405,743 shares of the company’s stock worth $389,174,000 after purchasing an additional 38,596 shares in the last quarter. Franklin Resources Inc. grew its position in Vaxcyte by 13.2% during the 3rd quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company’s stock valued at $315,162,000 after purchasing an additional 324,560 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Vaxcyte by 10.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,700,782 shares of the company’s stock valued at $308,675,000 after purchasing an additional 259,010 shares during the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.